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Purpose: The aim of this study was to define the immunoreactive specificity of Porphyromonas gingivalis (P. gingivalis) heat 
shock protein (HSP) 60 in periodontitis and atherosclerosis. 
Methods:  In an attempt to define the cross-reactive bacterial heat-shock protein with human self-antigen at molecular level, 
we have introduced a novel strategy for cloning hybridoma producing anti-P. gingivalis HSP 60 which is polyreactive to bacte-
rial HSPs or to the human homolog. 
Results:  Five cross-reactive clones were obtained which recognized the #19 peptide (TLVVNRLRGSLKICAVKAPG) among 37 
synthetic peptides (20-mer, 5 amino acids overlapping) spanning the whole molecule of P. gingivalis HSP 60. We have also es-
tablished three anti-P. gingivalis HSP 60 monoclonal antibodies demonstrating mono-specificity. These clones recognized 
the #29 peptide (TVPGGGTTYIRAIAALEGLK). 
Conclusions:  Peptide #19 and #29 of P. gingivalis HSP 60 might be important immunoreactive epitopes in the immuno-
pathogenic mechanism of bacterial antigen-triggered autoimmune diseases.
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INTRODUCTION
The crucial role of Porphyromonas gingivalis (P. gingivalis) 
heat shock protein (HSP)60 in the immunopathogenic mech-
anism of both periodontitis and atherosclerosis has been 
demonstrated in the context of immunodominant T- and/or 
B-cell epitopes in our previous studies [1-4]. Also we have re-
cently reported that vaccines formulated with P. gingivalis 
HSP60 can successfully reduce the alveolar bone loss in ex-
perimental periodontitis as a polymicrobial infection [5] and 
that anti-P. gingivalis HSP60 antibody manifested cross-spe-
cies recognition to exert an opsonophagocytic function 
against multiple periodontopathogenic bacteria [6]. However, 
a concern about potential autoimmune reaction may arise 
inherent from the high level of sequence homology of bacte-
rial HSP with human self-antigen when the whole HSP60 
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molecule is considered for vaccine administration. 
Nonetheless, identifying a defined cross-reactive bacterial 
peptide antigen is of critical value in several ways including 1) 
for identifying the putative peptide antigen responsible for 
inducing or suppressing autoimmunity in host, 2) for identi-
fying a candidate peptide vaccine to provide cross-species 
immunity, or 3) for use as a tool for mobilizing antigen-specif-
ic regulatory T cells to suppress autoimmune diseases. Thus, 
defining a peptide molecule from bacterial HSP60 that is 
cross-reactive with human HSP60 at the molecular level 
would be an exciting idea for stimulating antigen-specific 
regulatory T cells that might suppress a P. gingivalis HSP-
triggered autoimmune response either in periodontitis as an 
infectious disease [7] or atherosclerosis as an autoimmune 
disease [8]. In the same way, identifying bacterial HSP60 
peptide that exhibits cross-species recognition would facili-
tate peptide vaccine development for protection against 
periodontitis as a polymicrobial disease.
However, simply comparing sequence similarity (homolo-
gy) or mapping immunodominant epitopes might provide 
only limited information on which peptide of P. gingivalis 
HSP does cross-react with human HSP peptide within the 
gingival lesion or arterial wall at the molecular level. To cir-
cumvent these underlying obstacles, we have adopted an in-
novative strategy to incorporate the monoclonal hybridoma 
technology to screen candidate peptides that may manifest 
poly-specificities to exogenous bacterial or to indigenous hu-
man self-antigens at molecular level. This concept stems from 
the polyreactive nature of antibodies to pathogen-associated 
molecular pattern such as HSP, lipopolysaccharide, or phos-
phorylcholine [9-11]. Identifying a P. gingivalis HSP peptide 
sequence recognized by the monoclonal antibody would thus 
enable us to clarify the exact immunodominant peptide 
epitope(s) responsible for eliciting in vivo cross-reactivity to 
its human counterpart.
The primary goal of the present study was to propose an 
innovative monoclonal hybridoma technology to define an 
immunodominant epitope of P. gingivalis HSP60 either 
mono-specific to its cognate antigen or poly-specific to other 
bacterial HSP’s or with a human homolog,
MATERIALS AND METHODS
Production of monoclonal antibody against P. gingivalis 
HSP60
Immunization of mice with recombinant P. gingivalis HSP60
Recombinant P. gingivalis HSP60 was purified from the P. 
gingivalis GroEL gene (a gift from Dr. Yoji Murayama, Okaya-
ma, Japan) as previously reported [2,6]. C57BL/6 mice (Jackson 
Laboratory, Bar Harbor, ME, USA) were initially immunized 
subcutaneously with 50 g of recombinant P. gingivalis HSP60 
emulsified in complete Freund’s adjuvant followed by two 
subsequent subcutaneous injections of the HSP60 in incom-
plete Freund’s adjuvant. Animals were bred and maintained 
in a specific-pathogen-free animal breeding facility, the ex-
periments were conducted according to Declaration of Hel-
sinki principles, and the experimental protocol was approved 
by the Institutional Review Board of Pusan National Univer-
sity Hospital.
Establishment of hybridoma producing anti-P. gingivalis HSP60 
IgG antibody
Two weeks after the final immunization, mouse spleen cells 
were homogenized to a single cell by passing them through 
30 μm nylon mesh (Miltenyi Biotech GmbH, Bergisch Glad-
bach, Germany) and suspended in serum-free Dulbecco’s 
modification of eagle’s medium (DMEM). The harvested 
cells were lysed of contaminating red blood cells and resus-
pended to fuse with the same number of mouse myeloma 
cells (SP2/0-Ag14, American Type Culture Collection #CRL 
1581) in the presence of 50% polyethylene glycol. The fused 
cells were incubated in DMEM containing 20% fetal bovine 
serum, and then incubated in hypoxanthine-aminopterin-
thymidine-containing media for 2 weeks to remove unfused 
cells. The selection procedure was terminated by adding hy-
poxanthine-thymidine-containing media. Wells with single 
foci of homogeneous cells were identified to collect culture 
supernatants and were screened for secretion of the anti-P. 
gingivalis HSP60 IgG antibody. To ensure the monoclonality 
of the cells, limiting dilution was performed down to 0.3 cell/
well in 96-well plates until hybridoma producing anti-P. gin-
givalis HSP60 IgG antibody was finally identified.
Screening culture supernatants producing IgG antibody to P. gin-
givalis HSP60
Microtiter plates coated with P. gingivalis HSP60, diluted in 
10 mM phosphate buffer [12-14], were incubated with an ali-
quot of cell culture supernatants. After samples were washed, 
horseradish peroxidase-conjugated goat anti-mouse IgG 
(γ-chain specific, Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA, USA) was added. After incubation for 2 hours 
at room temperature, the plates were washed, and an aliquot 
of tetramethylbenzidine (Kirkegaard and Perry Laboratories, 
Gaithersburg, MD, USA) was added for incubation, followed 
by the addition of 0.18 M H2SO4 to stop the color develop-
ment. Optical densities (OD) were plotted as a function of 
the serum dilution factor. Serum dilution factor correspond-
ing to an optical density of 0.5 was assigned an ELISA unit. 
The wells producing antibody units higher than a mean OD+ 
3×s.d. were identified as being positive.Journal of Periodontal
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Production and purification of anti-P. gingivalis HSP60 mono-
clonal antibody
The established hybridoma cells were expanded and 2×10
6 
cells were injected into the peritoneal cavity of the C57BL/6 
mouse that had been immune-suppressed previously by an 
intraperitoneal injection of immunosuppressant (500 μL/
mouse, Pristane, Sigma-Aldrich Co., St. Louis, MO, USA). As-
cites fluid was collected by needle aspiration and anti-P. gin-
givalis monoclonal IgG antibody was purified by using an 
immunoglobulin G purification system (ImmunoPure, 
Pierce Chemical Co., Rockford, IL, USA).
Screening purified monoclonal antibody for cross-reactivity 
with other bacterial HSP’s and human HSP60 by Western 
immunoblot
Five μg of recombinant P. gingivalis HSP60, 100 μg of ly-
sate preparations from five bacterial species, and 5 μg of hu-
man HSP60 (StressGen Biotechnologies Co., Victoria, Cana-
da) were subjected to sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and electro-transferred to 
nitrocellulose membrane. After blocking the membrane, pu-
rified anti-P. gingivalis HSP60 monoclonal antibody was ap-
plied for incubation. The membrane was washed and orse-
radish peroxidase-conjugated mouse anti-mouse IgG was 
added. After washing the membrane, tetramethylbenzidine 
was added for visualization of bound antibodies. Bacterial 
cell lysates was prepared by sonicating five periodontopathic 
bacterial cells consisting of P. gingivalis, Actinobacillus actino-
mycetemcomitans, Prevotella intermedia, Treponema denticola, 
Streptococcus mutans, and Fusobacterium nucleatum that had 
been anaerobically grown and then heat-shocked for 1 hour 
at 44°C. We loaded 100 μg of bacterial cell lysate proteins, be-
ing equivalent to approximately 5 μg of HSP’s, for semiquan-
titative comparison of blotting intensity. This method was 
derived from the idea that heat-inducible protein, represent-
ing 1 to 2% of total bacterial proteins under normal conditions, 
increases four- to five-fold under heat shock treatment [15]. 
Identification of specific peptide epitope recognized by 
mono-specific or poly-specific anti-P. gingivalis HSP60 
monoclonal antibody
Construction of synthetic peptides
A total of 37 overlapping peptides, each consisting of 20 
amino acid with 5 amino acids overlapping, spanning whole 
molecule of P. gingivalis HSP60 were synthesized by Fmoc 
solid phase peptide synthesis using ASP48S (Peptron Inc., 
Daejeon, Korea) and purified by the reverse phase HPLC us-
ing a Vydac Everest C18 column. Elution was carried out with 
a water-acetonitrile linear gradient (10 to 75% (v/v) of aceto-
nitrile) containing 0.1% (v/v) trifluoroacetic acid.
Dot immunoblot analysis
Briefly, each peptide (1 μg) was spotted onto polyvinyliden 
fluoride membrane. The membrane was blocked with 5% 
skim milk followed by adding the monoclonal antibody in 
phosphate buffered saline (PBS) buffer for incubation for 2 
hours at room temperature. After washing the membrane, 
horseradish peroxidase-conjugated goat anti-mouse IgG was 
added for 1 hour. The membrane was then washed with PBS-
Tween followed by adding tetramethylbenzidine for color 
development.
RESULTS
Production of monoclonal antibody against P. gingivalis 
HSP60
A total of eight anti-P. gingivalis HSP60 IgG monoclonal 
antibodies were cloned and each was subjected to SDS-PAGE 
for verification of purity consisting of heavy and light chain 
molecules of IgG antibody, respectively (Fig. 1).
Screening purified monoclonal antibody for cross-reactivity 
with other bacterial HSP’s and human HSP60 by western 
immunoblot
Each purified monoclonal antibody was examined for its 
reactivity with recombinant P. gingivalis HSP60, bacterial 
HSP proteins, or human HSP60, respectively, by western im-
munoblot. Based on their mono- or poly-reactivity with dif-
ferent HSP’s, two different panels of monoclonal antibodies 
have been categorized: one being mono-specific to cognate 
P. gingivalis HSP60, the other being poly-specific to different 
70 K
50 K
60 K
MW       HSP JC2
Heavy chain
Light chain
A B
Figure 1. Sodium dodecyl sulfate polyacrylamide gel electrophore-
sis profile of purified recombinant Porphyromonas gingivalis HSP60 
(A) and one (clone JC2) of purified anti-P. gingivalis HSP60 mono-
clonal IgG antibody demonstrating the heavy and the light chain, 
respectively (B). MW: molecular weight marker, HSP: heat shock 
protein.Journal of Periodontal
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bacterial HSP’s and human HSP60 (Figs. 2 and 3). 
Identification of a specific peptide epitope recognized by 
mono-specific or poly-specific anti-P. gingivalis HSP60 
monoclonal antibody
We were able to obtain eight clones from mouse hybrid-
oma producing a panel of monoclonal IgG antibodies to P. 
gingivalis HSP60 which was used for the immunogenic anti-
gen. Five clones (JC5-JC9) of poly-specific anti-P. gingivalis 
HSP60 monoclonal antibodies recognized #19 synthetic 
peptide, while three clones (JC1-JC3) of mono-specific anti-P. 
gingivalis HSP60 monoclonal antibodies recognized peptide 
#29 of synthetic peptide spanning the whole molecule of P. 
gingivalis HSP60, as evidenced by dot immunoblot analyses 
(Fig. 4). For further characterization of the five poly-reactive 
monoclonals, we have synthesized #19 peptides based on 
known sequences of human HSP60, Mycobacterium tubercu-
losis (M. tuberculosis), and Chlamydia pneumoniae (C. pneu-
moniae) and tested them for inter-species cross-reactivity 
with non-oral pathogens. In addition to reactivity with pep-
tide #19 from human HSP60, all of the clones have demon-
strated inter-species cross-reactivity with peptide #19 from C. 
pneumoniae, but not with that of M. tuberculosis as shown by 
dot immunoblot analysis (Fig. 5). The peptide specificities of 
cloned monoclonal antibodies are summarized in Table 1.
Table 1. One-letter amino acid sequences of peptide #19 and #29 of 
Porphyromonas gingivalis HSP60 recognized by five poly-reactive 
(JC5-JC9) or three mono-reactive clones (JC1-JC3), respectively.
Clones Synthetic peptide # One-letter amino acid sequence
JC5-JC9 #19 TLVVNRLRGSLKICAVKAPG
JC1-JC3 #29 TVPGGGTTYIRAIAALEGLK
JC1
JC2
JC3
Hu
HSP60
Pg
HSP60
JC5
JC6
JC7
Hu
HSP60
Pg
HSP60
JC8
JC9 A B
Figure 2. Reactive pattern of cross-reactive (A: clones JC5-JC9) and 
mono-reactive (B: clones JC1-JC3) or anti-Porphyromonas gingivalis 
heat shock protein 60 monoclonal antibodies with cognate antigen 
or with human counterpart demonstrated by immunoblot analysis.
JC5 JC1
JC6 JC2
JC7 JC3
JC8
JC9
Pg
HSP60
Pg
HSP60
Aa Aa Pi Pi Fn Fn Sm Sm Td Td
A B
Figure 3. Reactive pattern of poly-reactive (A: clones JC 5-JC9) and 
mono-reactive (B: clones JC1-JC3) anti-Porphyromonas gingivalis 
heat shock protein (HSP)60 monoclonal antibodies with cognate 
HSP antigen or with HSP’s of five periodontopathogenic bacteria 
as demonstrated by immunoblot analysis. Pg: P. gingivalis HSP60, 
Aa: Actinobacillus actinomycetemcomitans, Pi: Prevotella intermedia, 
Fn: Fusobacterium nucleatum, Sm: Streptococcus mutans, Td: Trepone-
ma denticola.
A B
Clones JC5-JC9 Clones JC1-JC3
Figure 4. Poly-reactive monoclonal antibody (A: clones JC5-JC9) rec-
ognized #19 peptide among 37 synthetic peptides spanning a whole 
molecule of Porphyromonas gingivalis heat shock protein (HSP)60 as 
well as human HSP60, while mono-reactive monoclonal antibody 
(B: clones JC1-JC3) recognized #29 peptide among the same syn-
thetic peptides without responding to human HSP60, as evidenced 
by dot immunoblot analyses. Hu: human HSP60, Pg: P. gingivalis 
HSP60.
JC5
Hu#19
Pg#19
Myco#19
Chia#19
JC6
JC7
JC8
JC9
Figure 5. In addition to reactivity with peptide #19 (Hu#19) from 
self-antigen (human heat shock protein 60), inter-species cross-re-
activity of the five monoclonal antibodies (clones JC5-JC9) with #19 
synthetic peptides from Porphyromonas gingivalis (Pg#19), Mycobac-
terium tuberculosis (Myco#19) and Chlamydia pneumoniae (Chla#19), 
respectively, is demonstrated by dot immunoblot analysis. Note 
that none of them recognized #19 peptide from M. tuberculosis.Journal of Periodontal
& Implant Science JPIS
Monoclonal antibody to Porphyromonas gingivalis heat-shock protein 60 58
DISCUSSION
Despite the monoclonality of hybridoma cell lines estab-
lished in the course of limiting dilution, five of them exhibit-
ed an identical pattern of polyreactivity with cognate HSP 
antigen and other bacterial HSP’s, as well as to human ho-
molog, while three of them demonstrated a monoreactivity 
to cognate HSP60 molecule. Thus, in this study it was possi-
ble to validate polyreactive monoclonal antibody, one of the 
characteristic features of host defense mechanisms against 
pathogen-associated molecular pattern, such as bacterial 
heat shock protein [9-11]. In an attempt to identify the specif-
ic epitope recognized by these monoclonal antibodies, we 
have synthesized 37 synthetic peptides (20 mer, 5 amino acids 
overlapping) spanning the whole molecule of P. gingivalis 
HSP60. Monoreactive monoclonal antibody to P. gingivalis 
HSP60 recognized peptide #29 (TVPGGGTTYIRAIAALEGLK), 
while polyreactive monoclonal antibody recognized peptide 
#19 (TLVVNRLRGSLKICAVKAPG). To confirm the cross-re-
activity, we have synthesized peptide #19 from known se-
quences of human HSP60 molecule as well as lysate prepa-
ration from heat-induced whole bacterial cellular protein, 
which were used for immunoblot analysis. The cross-reactiv-
ity of the five monoclonal antibodies with synthetic peptide 
#19 from human HSP60 was confirmed by dot immunoblot. 
Here, we propose the monoclonal hybridoma technology as 
a novel strategy for elucidating cross-reactive immunodomi-
nant epitope(s) at a molecular level in autoimmune diseases.
Interestingly, based on our series studies and other report, 
peptide #19 has been immunodominant T-and B-cell epit-
ope in both periodontitis and atherosclerosis patients [2,4,16, 
17] and common B-cell epitope in atherosclerosis patients [2], 
while peptide #29 has been B-cell epitope in periodontitis [12] 
and T- and B-cell epitope in atherosclerosis patients. Though 
our previous epitope mapping results may indicate that both 
peptide #19 and #29 might be involved in the immunopath-
ologic process in atherosclerosis as an autoimmune disease, 
the latter may not be involved in the autoimmune pathologic 
process of atherosclerosis at the molecular level based on the 
monoclonal hybridoma technology-based approach intro-
duced in our present study. The present study strongly sug-
gests that peptide #19 may be an immunodominant epitope 
that demonstrates a robust cross-reactivity with other bacte-
rial and human HSP60. Hence, peptide #19 may be respon-
sible for either inducing or suppressing autoimmunity by the 
host, because cross-reactive peptide to self-antigen is known 
to mobilize antigen-specific regulatory T cells to suppress 
autoimmune diseases [18]. Potentially it could also be a can-
didate peptide for developing a vaccine to provide cross-spe-
cies immunity in periodontitis as a polymicrobial infectious 
disease. HSP60 is widely known to be a molecular target for 
the T-cell immune response in the periodontitis-atheroscle-
rosis link [2,8,19,20]. Hence, the polyclonal anti-P. gingivalis 
HSP60 antibody could exert either a protective or deteriorat-
ing effect on experimental periodontitis induced by multiple 
bacterial infection. Currently we have launched a series of 
studies aimed at evaluating the significant role of peptide 
#19 in the immunopathogenic mechanism of periodontitis 
or atherosclerosis. 
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